Yan Xia
Director, ADC Research Huadong Medicine Co.,Ltd
Dr. Yan Xia has been the Director of ADC Research Center at Huadong Medicine in Hangzhou, China since 2022. He leads the early research and development of the ADC pipeline. Do date, his team has pushed 5 ADC projects into clinical studies with unique focus on GI cancers. Previously, Dr Xia served as senior scientist. In this position, he led the preclinical biology team and conducted several projects in oncology and metabolic diseases. Dr. Xia holds a Ph.D. in chemical and physical biology from Vanderbilt University, Nashville, Tennessee, USA, and a B.Sc. in biological sciences from Nanyang Technological University, Singapore.
Seminars
Wednesday 14th October 2026
Advancing a Novel Target Against Gastrointestinal Cancer to Undergo ADC Development in a Currently Underserved Indication
2:30 pm
- Delving into novel ADC target FGFR2b, MUC17 and CDH17 to treat gastrointestinal cancer, an indication currently underserved by ADC therapies
- Exploring preclinical and clinical development of CDH17 ADC in colorectal cancer
- Complementing bispecific design and linker-payload DAR optimization for next generation bispecific ADCs
